NO20022124L - Imidazopyridinderivater som fosfodiesterase VII-inhibitorer - Google Patents
Imidazopyridinderivater som fosfodiesterase VII-inhibitorerInfo
- Publication number
- NO20022124L NO20022124L NO20022124A NO20022124A NO20022124L NO 20022124 L NO20022124 L NO 20022124L NO 20022124 A NO20022124 A NO 20022124A NO 20022124 A NO20022124 A NO 20022124A NO 20022124 L NO20022124 L NO 20022124L
- Authority
- NO
- Norway
- Prior art keywords
- atoms
- imidazopyridine derivatives
- phosphodiesterase vii
- vii inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Forbindelser med formel (I) hvor R1 betyr CONR4R5; R2 betyr H eller A; R3 betyr Hal; R4 og R5 betyr hver uavhengig av hverandre H eller A1; Hal betyr F, Cl, Br eller I; A betyr alkyl med 1-4 C-atomer; A1 betyr alkyl med l -10 C-atomer; og X betyr alkylen med 1-4 C-atomer; idet en etylengruppe også kan være erstattet med en dobbelt- eller trippelbinding, og deres fysiologisk akseptable salter og/eller solvater, som fosfodiesterase VH-inhibitorer, og deres anvendelse til fremstilling av et legemiddel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19953414A DE19953414A1 (de) | 1999-11-06 | 1999-11-06 | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
PCT/EP2000/010525 WO2001034601A2 (de) | 1999-11-06 | 2000-10-25 | Imidazopyridinderivate als phosphodiesterase vii-hemmer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022124D0 NO20022124D0 (no) | 2002-05-03 |
NO20022124L true NO20022124L (no) | 2002-05-03 |
Family
ID=7928107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022124A NO20022124L (no) | 1999-11-06 | 2002-05-03 | Imidazopyridinderivater som fosfodiesterase VII-inhibitorer |
Country Status (22)
Country | Link |
---|---|
US (1) | US6613778B1 (no) |
EP (1) | EP1226143B1 (no) |
JP (1) | JP2003513973A (no) |
KR (1) | KR20020044591A (no) |
CN (1) | CN1387530A (no) |
AR (1) | AR026352A1 (no) |
AT (1) | ATE236157T1 (no) |
AU (1) | AU775993B2 (no) |
BR (1) | BR0015324A (no) |
CA (1) | CA2388729A1 (no) |
CZ (1) | CZ20021416A3 (no) |
DE (2) | DE19953414A1 (no) |
DK (1) | DK1226143T3 (no) |
ES (1) | ES2192183T3 (no) |
HU (1) | HUP0203245A3 (no) |
MX (1) | MXPA02004448A (no) |
NO (1) | NO20022124L (no) |
PL (1) | PL355022A1 (no) |
PT (1) | PT1226143E (no) |
SK (1) | SK5732002A3 (no) |
WO (1) | WO2001034601A2 (no) |
ZA (1) | ZA200204510B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4312603B2 (ja) | 2001-12-13 | 2009-08-12 | アスビオファーマ株式会社 | Pde7阻害作用を有するピラゾロピリミジノン誘導体 |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
JP2006219374A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
DK1775298T3 (da) * | 2004-07-01 | 2013-05-21 | Daiichi Sankyo Co Ltd | Thienopyrazolderivat med PDE7-inhibitorisk aktivitet |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
AU2008230710B2 (en) * | 2007-03-27 | 2014-04-10 | Omeros Corporation | The use of PDE7 inhibitors for the treatment of movement disorders |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN103547267A (zh) | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
MX2020000295A (es) | 2017-07-12 | 2020-07-22 | Dart Neuroscience Llc | Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3150486A1 (de) * | 1981-12-19 | 1983-08-25 | Merck Patent Gmbh, 6100 Darmstadt | Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
US5120740A (en) * | 1989-11-03 | 1992-06-09 | Wisconsin Alumni Research Foundation | Prodrugs of 6-mercaptopurine and 6-thioguanine |
-
1999
- 1999-11-06 DE DE19953414A patent/DE19953414A1/de not_active Withdrawn
-
2000
- 2000-10-25 ES ES00975916T patent/ES2192183T3/es not_active Expired - Lifetime
- 2000-10-25 CZ CZ20021416A patent/CZ20021416A3/cs unknown
- 2000-10-25 SK SK573-2002A patent/SK5732002A3/sk unknown
- 2000-10-25 EP EP00975916A patent/EP1226143B1/de not_active Expired - Lifetime
- 2000-10-25 JP JP2001536548A patent/JP2003513973A/ja active Pending
- 2000-10-25 US US10/129,274 patent/US6613778B1/en not_active Expired - Fee Related
- 2000-10-25 CA CA002388729A patent/CA2388729A1/en not_active Abandoned
- 2000-10-25 PT PT00975916T patent/PT1226143E/pt unknown
- 2000-10-25 CN CN00815292A patent/CN1387530A/zh active Pending
- 2000-10-25 DE DE50001663T patent/DE50001663D1/de not_active Expired - Lifetime
- 2000-10-25 DK DK00975916T patent/DK1226143T3/da active
- 2000-10-25 MX MXPA02004448A patent/MXPA02004448A/es unknown
- 2000-10-25 HU HU0203245A patent/HUP0203245A3/hu unknown
- 2000-10-25 AT AT00975916T patent/ATE236157T1/de not_active IP Right Cessation
- 2000-10-25 WO PCT/EP2000/010525 patent/WO2001034601A2/de active IP Right Grant
- 2000-10-25 AU AU13872/01A patent/AU775993B2/en not_active Ceased
- 2000-10-25 PL PL00355022A patent/PL355022A1/xx unknown
- 2000-10-25 BR BR0015324-9A patent/BR0015324A/pt not_active Application Discontinuation
- 2000-10-25 KR KR1020027005848A patent/KR20020044591A/ko not_active Application Discontinuation
- 2000-11-03 AR ARP000105801A patent/AR026352A1/es unknown
-
2002
- 2002-05-03 NO NO20022124A patent/NO20022124L/no not_active Application Discontinuation
- 2002-06-05 ZA ZA200204510A patent/ZA200204510B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US6613778B1 (en) | 2003-09-02 |
MXPA02004448A (es) | 2004-09-10 |
PL355022A1 (en) | 2004-03-22 |
CN1387530A (zh) | 2002-12-25 |
BR0015324A (pt) | 2002-07-09 |
AU775993B2 (en) | 2004-08-19 |
KR20020044591A (ko) | 2002-06-15 |
HUP0203245A3 (en) | 2003-12-29 |
PT1226143E (pt) | 2003-08-29 |
WO2001034601A3 (de) | 2001-11-15 |
EP1226143A2 (de) | 2002-07-31 |
DE19953414A1 (de) | 2001-05-10 |
DK1226143T3 (da) | 2003-06-30 |
JP2003513973A (ja) | 2003-04-15 |
CA2388729A1 (en) | 2001-05-17 |
ES2192183T3 (es) | 2003-10-01 |
CZ20021416A3 (cs) | 2002-08-14 |
HUP0203245A2 (hu) | 2003-01-28 |
ATE236157T1 (de) | 2003-04-15 |
ZA200204510B (en) | 2003-11-26 |
NO20022124D0 (no) | 2002-05-03 |
EP1226143B1 (de) | 2003-04-02 |
AR026352A1 (es) | 2003-02-05 |
AU1387201A (en) | 2001-06-06 |
SK5732002A3 (en) | 2002-09-10 |
WO2001034601A2 (de) | 2001-05-17 |
DE50001663D1 (de) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20022124L (no) | Imidazopyridinderivater som fosfodiesterase VII-inhibitorer | |
IL150883A0 (en) | Pyrimidine compounds | |
DK1406876T3 (da) | 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser | |
BG103195A (en) | Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf) | |
DK1278735T3 (da) | 2,4-di(hetero-)arylamino(-oxy)-5-substituerede pyrimidiner som antineoplastiske midler | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
FI905758A0 (fi) | Menetelmä anti-tuumoriaineina käyttökelpoisten akryloyylisubstituoitujen pyrrolijohdannaisten valmistamiseksi | |
TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
WO2001014330A3 (en) | Phenylpiperazines as serotonin reuptake inhibitors | |
WO2001094345A3 (en) | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione | |
IL163625A0 (en) | Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same | |
NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
IL153748A0 (en) | Processes for preparing azacycloalkanoylaminothiazole derivatives | |
AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
PL378343A1 (pl) | Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny | |
ATE238300T1 (de) | (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine | |
NZ291855A (en) | Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists | |
NO20035026D0 (no) | Dihydroimidazo [5,1-A]-<beta>-karbolinderivater, fremgangsmåte til deres fremstilling og anvendelse derav som legemiddel | |
WO2002074764A3 (en) | Piperazine derivatives and their use as 5-ht1b ligands | |
CA2245484A1 (en) | Novel urea derivatives | |
GB0114699D0 (en) | Organic compounds | |
TH19525EX (th) | อนุพันธุ์ไพริโด (1,2,3-d,e) (1,3,4)เบนซอกซาไดอะซีน | |
TH19525A (th) | อนุพันธุ์ไพริโด (1,2,3-d,e) (1,3,4)เบนซอกซาไดอะซีน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |